Corazon (Corsee) Sanders Sells 212 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Director Corazon (Corsee) Sanders sold 212 shares of the business’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $309.59, for a total value of $65,633.08. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Performance

NASDAQ:ONC opened at $290.58 on Friday. The stock has a 50-day simple moving average of $301.92 and a two-hundred day simple moving average of $320.91. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $239.25 and a 52-week high of $385.22. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The firm has a market capitalization of $31.88 billion, a PE ratio of 65.01 and a beta of 0.50.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The business had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 5.65 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on ONC shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research note on Monday, April 20th. Barclays upped their price objective on BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Guggenheim upped their price objective on BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Morgan Stanley reaffirmed an “overweight” rating and issued a $395.00 price objective on shares of BeOne Medicines in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada upped their price objective on BeOne Medicines from $423.00 to $425.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $389.15.

Institutional Trading of BeOne Medicines

Institutional investors and hedge funds have recently made changes to their positions in the company. EFG International AG bought a new stake in shares of BeOne Medicines in the fourth quarter valued at about $25,000. Leonteq Securities AG bought a new stake in shares of BeOne Medicines in the fourth quarter valued at about $35,000. Daiwa Securities Group Inc. bought a new stake in shares of BeOne Medicines in the second quarter valued at about $35,000. CWM LLC raised its holdings in shares of BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after acquiring an additional 39 shares in the last quarter. Finally, Group One Trading LLC bought a new stake in shares of BeOne Medicines in the fourth quarter valued at about $61,000. 48.55% of the stock is currently owned by institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.